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Abstract: Epstein-Barr virus (EBV), a human gammaherpesvirus, is associated with a series 
of  malignant  tumors.  These  include  lymphomas  (Burkitt’s  lymphoma,  Hodgkin’s  disease, 
T/NK-cell  lymphoma,  post-
lymphoma, X-linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, 
gastric  carcinoma,  carcinomas  of  major  salivary  glands,  thymic  carcinoma,  mammary 
carcinoma) and a sarcoma (leiomyosarcoma). The latent EBV genomes persist in the tumor 
cells  as  circular  episomes,  co-
expression of latent EBV genes is cell type specific due to the strict epigenetic control of
promoters. DNA methylation, histone modifications and binding of key cellular regulatory 
proteins contribute to the regulation of alternative promoters for transcripts encoding the 
nuclear antigens EBNA1 to 6 and affect the activity of promoters for
transmembrane proteins (LMP1, LMP2A, LMP2B). In addition to genes transcribed by RNA 
polymerase II, there are also two RNA polymerase III transcribed genes in the EBV genome 
(EBER 1 and 2). The 5’ and internal regulatory sequences of 
units  are  invariably  unmethylated.  The  highly  abundant  EBER  1  and  2  RNAs  are  not 
translated to protein. Based on the cell type specific epigenetic marks associated with latent 
EBV genomes one can distinguish between viral epigeno
activity in spite of having an identical (or nearly identical) DNA sequence. Whereas latent 
EBV genomes are regularly targeted by epigenetic control mechanisms in different cell types, 
EBV  encoded  proteins  may,  in  turn,
interacting with the very same epigenetic regulatory machinery. There are EBNA1 binding 
sites in the human genome. Because high affinity binding of EBNA1 to its recognition sites is 
known to specify sites of DNA demethylation, we suggest that binding of EBNA1 to its cellular 
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Barr virus (EBV), a human gammaherpesvirus, is associated with a series 
of  malignant  tumors.  These  include  lymphomas  (Burkitt’s  lymphoma,  Hodgkin’s  disease, 
-transplant  lymphoproliferative  disease,  AIDS
linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, 
gastric  carcinoma,  carcinomas  of  major  salivary  glands,  thymic  carcinoma,  mammary 
d a sarcoma (leiomyosarcoma). The latent EBV genomes persist in the tumor 
-replicating  with  the  cellular  DNA  once  per  cell  cycle.  The 
expression of latent EBV genes is cell type specific due to the strict epigenetic control of
promoters. DNA methylation, histone modifications and binding of key cellular regulatory 
proteins contribute to the regulation of alternative promoters for transcripts encoding the 
nuclear antigens EBNA1 to 6 and affect the activity of promoters for
transmembrane proteins (LMP1, LMP2A, LMP2B). In addition to genes transcribed by RNA 
polymerase II, there are also two RNA polymerase III transcribed genes in the EBV genome 
(EBER 1 and 2). The 5’ and internal regulatory sequences of EBER 1 and 2 transcription 
units  are  invariably  unmethylated.  The  highly  abundant  EBER  1  and  2  RNAs  are  not 
translated to protein. Based on the cell type specific epigenetic marks associated with latent 
EBV genomes one can distinguish between viral epigenotypes that differ in transcriptional 
activity in spite of having an identical (or nearly identical) DNA sequence. Whereas latent 
EBV genomes are regularly targeted by epigenetic control mechanisms in different cell types, 
EBV  encoded  proteins  may,  in  turn, affect  the  activity  of  a  set  of  cellular  promoters  by 
interacting with the very same epigenetic regulatory machinery. There are EBNA1 binding 
sites in the human genome. Because high affinity binding of EBNA1 to its recognition sites is 
tes of DNA demethylation, we suggest that binding of EBNA1 to its cellular 
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Barr virus (EBV), a human gammaherpesvirus, is associated with a series 
of  malignant  tumors.  These  include  lymphomas  (Burkitt’s  lymphoma,  Hodgkin’s  disease, 
transplant  lymphoproliferative  disease,  AIDS-associated 
linked lymphoproliferative syndrome), carcinomas (nasopharyngeal carcinoma, 
gastric  carcinoma,  carcinomas  of  major  salivary  glands,  thymic  carcinoma,  mammary 
d a sarcoma (leiomyosarcoma). The latent EBV genomes persist in the tumor 
replicating  with  the  cellular  DNA  once  per  cell  cycle.  The 
expression of latent EBV genes is cell type specific due to the strict epigenetic control of their 
promoters. DNA methylation, histone modifications and binding of key cellular regulatory 
proteins contribute to the regulation of alternative promoters for transcripts encoding the 
transcripts encoding 
transmembrane proteins (LMP1, LMP2A, LMP2B). In addition to genes transcribed by RNA 
polymerase II, there are also two RNA polymerase III transcribed genes in the EBV genome 
EBER 1 and 2 transcription 
units  are  invariably  unmethylated.  The  highly  abundant  EBER  1  and  2  RNAs  are  not 
translated to protein. Based on the cell type specific epigenetic marks associated with latent 
types that differ in transcriptional 
activity in spite of having an identical (or nearly identical) DNA sequence. Whereas latent 
EBV genomes are regularly targeted by epigenetic control mechanisms in different cell types, 
affect  the  activity  of  a  set  of  cellular  promoters  by 
interacting with the very same epigenetic regulatory machinery. There are EBNA1 binding 
sites in the human genome. Because high affinity binding of EBNA1 to its recognition sites is 
tes of DNA demethylation, we suggest that binding of EBNA1 to its cellular Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
target sites may elicit local demethylation and contribute thereby to the activation of silent 
cellular promoters. EBNA2 interacts with histone acetyltransferases, and EBNALP (EBNA5) 
coactivates transcription by displacing histone deacetylase 4 from EBNA2-bound promoter 
sites. EBNA3C (EBNA6) seems to be associated both with histone acetylases and deacetylases, 
although  in  separate  complexes.  LMP1,  a  transmembrane  protein  involved  in  malignant 
transformation, can affect both alternative systems of epigenetic memory, DNA methylation 
and the Polycomb-trithorax group of protein complexes. In epithelial cells LMP1 can up-
regulate  DNA  methyltransferases  and,  in  Hodgkin  lymphoma  cells,  induce  the  Polycomb 
group protein Bmi-1. In addition, LMP1 can also modulate cellular gene expression programs 
by affecting, via the NF-κB pathway, levels of cellular microRNAs miR-146a and miR-155. 
These  interactions  may  result  in  epigenetic  dysregulation  and  subsequent  cellular 
dysfunctions that may manifest in or contribute to the development of pathological changes 
(e.g.  initiation  and  progression  of  malignant  neoplasms, autoimmune  phenomena,
immunodeficiency). Thus, Epstein-Barr virus, similarly to other viruses and certain bacteria, 
may induce pathological changes by epigenetic reprogramming of host cells. Elucidation of 
the epigenetic consequences of EBV-host interactions (within the framework of the emerging 
new  field  of  patho-epigenetics)  may  have  important  implications  for  therapy  and  disease 
prevention, because epigenetic processes are reversible and continuous silencing of EBV genes 
contributing to patho-epigenetic changes may prevent disease development. 
Introduction: Epstein-Barr virus (EBV), a member 
of  the  Gammaherpesvirinae subfamily,  is  a 
herpesvirus  widespread  in  human  populations
1. 
EBV  infects  B  lymphocytes  via the  complement 
receptor CD21, and the B-cell-bound virions can be 
transferred  efficiently  to  CD21-negative  epithelial 
cells
2. Thus,  when transmitted orally, EBV enters 
the  epithelial  cells  of the  oropharynx  resulting  in 
productive  (lytic)  infection.  On  the  contrary,  the 
EBV-B  cell  interaction  is  usually  nonproductive, 
the latent viral genomes persist as circular episomes 
and co-replicate with the cellular DNA once per cell 
cycle.
The  association  of  latent  EBV  genomes  with 
malignant tumors is well documented. The virus has 
been  discovered  in  cells  derived  from  endemic 
Burkitt’s  lymphoma  samples
3.  In  addition,  other 
lymphomas  (X-linked  lymphoproliferative 
syndrome,  posttransplant  lymphoproliferative 
disease,  AIDS-associated  lymphoma,  peripheral 
T/NK-cell  lymphoma,  Hodgkin’s  lymphoma), 
certain  carcinomas  (nasopharyngeal  carcinoma, 
gastric carcinoma, carcinomas of the major salivary 
glands,  thymic  carcinoma,  mammary  carcinoma) 
and  a  sarcoma  (leiomyosarcoma)  also  regularly 
carry latent EBV genomes
1,4 (Table 1). 
Sequencing of the 172 kb double stranded linear 
genome  of  the  prototype  EBV  strain  (B95-8) 
significantly  contributed  to  the  identification  of 
latent, growth-transformation associated proteins of 
the virus
5. 
During  productive  infection  all  EBV  encoded 
proteins are expressed and concatemeric replication 
of circular viral DNA templates is initiated at oriLyt 
(the lytic  origin of replication) by the  viral DNA 
polymerase  with  the  help  of  EBV  encoded 
transactivator and replication proteins
6,7,8 (Figure 1)
Table 1. Major EBV associated neoplasms (for details see 
Niller et al, 2007 and 2008).
Lymphomas
 Burkitt’s lymphoma
 Hodgkin’s disease
 T/NK-cell lymphoma
 X-linked lymphoproliferative disease
 Posttransplant lymphoproliferative disease
 AIDS-associated lymphoma
 Lymphomas  in  metothrexate-treated  rheumatoid 
arthritis and polymyositis patients
Carcinomas
 Nasopharyngeal carcinoma
 Gastric carcinoma
 Carcinomas of the major salivary glands
 Thymic carcinoma
 Mammary carcinoma
Sarcoma
 LeiomyosarcomaMedit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 1. Alternative origins of EBV DNA replication: In A, the synchronous replication of latent EBV episomes and the cellular 
DNA (i.e. the chromosomal site where the episome is teethered by EBNA1) is demonstrated. EBNA1 (not shown on the figure) binds 
to oriP,  the latent origin of EBV  DNA replication,  and it is  anchored to a possibly AT rich  chromosomal site  as  well. After 
replication, duplicated EBV episomes bind to the duplicated sites on adjacent sister chromatids (based on Nanbo et al.
10). In B, 
concatemeric replication is initiated during the lytic cycle at oriLyt. After nuclease cleavage, double stranded linear EBV genomes 
with variable number of terminal repeats (TRs; their borders are indicated by vertical bars) are generated (based on Sato et al.
7).
The viral DNA packaged into the virion ends in 
terminal  repetitions  (TRs).  Soon  after  in  vitro
infection of B cells the TRs fuse with each other 
and  circular  episomes  are  generated  by 
amplification  of  a  single  copy  of  the  viral  DNA. 
Only a subset of the viral genes are transcribed from 
the latent EBV episomes that co-replicate with the 
cellular genome in the emerging B cell clones. It is 
noteworthy  that  during  latent, non-productive 
infection,  DNA  synthesis  is  initiated  at  a  distinct 
origin  of  replication  called  oriP (that  is  different 
from  oriLyt),  by  the  cellular  DNA  replication 
machinery
9,10 (Figure  1).  Expression  of  growth-
transformation-associated viral latency genes leads 
to  the  establishment  of  permanently  growing 
(immortal)  lymphoblastoid  cell  lines  (LCLs). The 
major  EBV-associated  malignancies  also  carry 
predominantly circular EBV DNA molecules. EBV 
infection  is  apparently  important  in  their 
development,  because  analysis  of  fused  TR 
sequences  showed  that  these  tumors  are  clonal 
proliferations of cells infected by EBV on a single 
occasion,  presumably  in  an  early  stage  of 
tumorigenesis
11 (Figure 2). 
Host  cell  phenotype-dependent  expression  of 
latent  EBV  genes:  EBV  latency  types:  The 
majority  of  EBV  encoded  proteins  is  involved  in 
productive  EBV  infection and  includes 
transactivators,  enzymes  necessary  for  viral  DNA 
amplification  and  structural  components  of  the 
virions.  There  is  a  sequential  order  of  gene 
activation in the course of the lytic cycle: immediate 
early genes (BZLF1 and BRLF1) are expressed first 
and activate the so called early genes. Late proteins 
are expressed after viral DNA synthesis
12. 
A  more  restricted  pattern  of  viral  gene 
expression  can  be  observed  in  latently  infected
cells. The latent EBV genomes carried by in vitro
transformed  LCLs  and  lymphoproliferations 
developing in recipients of organ or bone marrow 
transplants  express six  nuclear proteins (EBNAs). 
The  EBNA1-6  transcripts  are  initiated  at  the  C 
promoter (Cp, located to the BamHI C fragment of 
the viral genome), hence the term „Cp on” latency
(also called latency type III)
13 (Table 2, Figure 3). 
Cp is active only in B lymphoblasts
14. EBNA1 is 
required for stable maintenance of viral episomes, 
whereas EBNA2, the major transactivator protein of 
EBV  transactivates  both  viral  promoters  (Cp, 
LMP1p,  LMP2Ap,  LMP2Bp, see  below)  and 
promoters  of  cellular  genes  (CD23,  CD21). 
EBNA3-6  modulate  the  transactivator  activity  of 
EBNA2 (see below). 
In „Cp on” latency (reviewed by Niller et al.
1) 
one  can  also  detect  three  transcripts  for  latentMedit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Figure 2. Clonality of EBV-associated neoplasms: The double stranded linear EBV genomes packaged into virions have variable 
numbers of terminal repeats (TRs, bordered by vertical bars on the figure) at their ends. After infection of cells, the termini fuse 
forming a circular episome harbouring distinct numbers of TRs. Clones  of transformed cells can be characterized by determining the 
size of the BamHI fragment carrying the TRs (see Raab-Traub and Flynn
11).
membrane proteins (LMP1, LMP2A, LMP2B), two 
small RNA molecules (EBER 1 and 2), transcripts 
derived from the BamHI A fragment of the genome 
(BARTs, reviewed  by  Smith
15)  and  a  series  of 
microRNAs
16,17,18.  The  transmembrane  proteins 
LMP1 and LMP2 affect various signal transduction 
pathways.  Expression  of  LMP1  in  rodent  cells 
causes  malignant transformation.  The  EBERs and 
BARTs (and the protein products of BARTs), and 
the  BARF1  protein  were  also  implicated  in 
oncogenesis  (reviewed  by  Niller  et  al.
1).  The 
microRNAs derived from transcripts of the BHRF1
gene  and  the  BART  transcripts  may  target  both 
viral  and  cellular  RNAs  affecting  thereby  the 
abundance  of lytic  (BALF5)  and  latent  (LMP1) 
EBV  transcripts as  well  as certain  cellular RNAs 
(e.g. that of CXCL-11, coding for a chemokine) (for 
review see Swaminathan
19). 
In other EBV-carrying cell types Cp is switched 
off  („Cp  off”  latency).  These  include  memory  B
cells, Burkitt’s lymphomas (BLs) and BL cell lines 
that maintain the BL biopsy phenotype (type I BL 
cell  lines),  EBV-associated  carcinomas 
(nasopharyngeal carcinoma, gastric carcinoma) and 
Hodgkin’s  lymphomas.  In  „Cp  off  latency”
typically  an  alternative  promoter  (Q  promoter  or 
Qp) is used for expression of EBNA1 transcripts, 
but the transcripts coding for the other five EBNAs 
are absent. The various cell types carrying silent C 
promoters may differ from each other regarding the 
expression  of  LMPs,  BARTs,  BARF1  and  EBV-
encoded  microRNAs  (latency  types  0,  I  and  II,
Table 2, Figure 3)
1, 15,17. 
EBNA1 binds to oriP, the latent origin of EBV 
replication that acts as a long-range enhancer of Cp 
and LMP1p. This enhancer activity is essential for 
EBNA2  expression during  immortalization  of  B 
cells in vitro
20. In the absence of EBNA2 (the major 
viral transactivator protein in latency type III), the 
LMP promoters are activated by cellular proteins in 
nasopharyngeal carcinomas and in Sternberg-Reed 
cells of Hodgkin’s disease (latency type II), but not 
in  type  I  BL  cell  lines  or  BL  biopsies  (type  I 
latency)  or  memory  B  cells  (type  0  latency, 
characterized by variable Qp activity)
1. 
It was observed by several laboratories that EBV 
latency  promoter-reporter  constructs  were  active 
after  in  vitro  transfection  into  EBV  carrying  cell 
lines  even  if  the  corresponding  latency  promoter 
located  on the  viral  episomes  was  silent
21,22,23,24. 
This  observations  suggested  that  the  transfected 
cells  contained  the  transcription  factors  necessary 
for promoter activity and raised the possibility that 
silencing  of  latent  viral  promoters  may  be 
associated  with  their  inaccessibility  to  cellular 
transcription  factors.  In  the  next  part  we  briefly 
outline  the  epigenetic  modifications  and Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Table 2. Major latency types of Epstein-Barr virus
mechanisms  potentially  regulating  promoter 
accessibility.  
Epigenetic  modifications  and  epigenetic 
regulatory systems: Modified bases in the DNA of 
prokaryotes may serve as identification marks that 
permit  discrimination  between  self  and  foreign 
(invading)  DNA.  Well  characterized  endo-
deoxyribonuclease  (restriction  endonuclease)  and 
DNA  methyltransferase  (modification  methylase) 
activities,  recognizing  the  same  DNA  sequence, 
enable bacterial cells to resist infections by phage or 
plasmid DNA molecules that are unmethylated or 
methylated at recognition sites different from those 
marked  on  the  host  DNA  (reviewed  in  Wilson, 
1998, Bujnicki, 2001, Murray, 2002). In addition to 
inhibiting the activity of restriction endonucleases, 
sequence-specific  methylation  may  modulate 
(repress  or  activate)  the  expression  of  certain 
bacterial  gene  sets  as  well,  influencing  thereby 
bacterial  virulence
25,26.  Modified  bases  are  also 
involved  in  postreplicative  repair  processes  in 
bacteria and may contribute to membrane binding 
and segregation of the chromosome as well
27,28.
The role of base modification mediated by DNA 
methyltransferases  apparently  changed  in  large-
genome eukaryotes. Bestor proposed that in these 
organisms DNA methyltransferases perform a new 
function, the compartmentalization of the genome
29. 
This  would  provide  an  easy  access  to  the 
unmethylated fraction of the genome by diffusible 
regulatory  factors,  while  the  usually  larger, 
methylated fraction would remain inaccessible for 
them. One could argue that this novel function of 
DNA  methyltransferases  is  reflected  in  the 
discontinuous, and changing methylation patterns of 
vertebrate  genomes.  In  contrast  to  prokaryotes 
where the methyl-transferases modify essentially all 
of  their  recognition  sites,  in  vertebrates  there  are 
alternating  domains  of  methylated  and 
unmethylated regions, and the methylation patterns 
of a certain region may change during development 
and  differentiation  (tissue-specific  methylation 
patterns). The unmethylated domains, called CpG
Figure 3. Promoter switch in latent EBV episomes: After initial EBV infection of B cells in vitro, Wp (a promoter located to the 
BamHI W fragment of the EBV genome) is switched on. A giant transcript coding for 6 nuclear antigens (EBNA1-6) is generated but 
the activity of Wp is transient. The transactivator protein EBNA2 and the EBNA1-bound oriP enhancer may contribute to switching 
on Cp, a B lymphoblast specific promoter. Burkitt’s lymphoma (BL) cells use a different promoter, Qp, to generate a transcript for
EBNA1 only. In vitro cultivated BL cells may switch from Qp to Cp (arrow to the left). This promoter switch results in a phenotypic 
drift (from memory B cell to activated B cell phenotype). A Cp to Qp switch has been predicted but never observed (broken arrow) 
(see Niller et al.
13).
Latency type Representative cell type Expressed products
„Cp off latency”
Type 0 latency Resting B cell EBNA1 (variable ?), LMP2A (?)
Type I latency Burkitt’s lymphoma  EBNA1, EBER1 & 2, BART, microRNAs
Type II latency Hodgkin’s lymphoma EBNA1, EBER1 & 2, BART, LMP1 & 2, microRNAs
Nasopharyngeal  and EBNA1, EBER1 & 2, BART,
gastric carcinoma LMP1 (variable expression), LMP2, microRNAs, BARF1
„Cp on latency”
Lymphoblastoid cell lines EBNA1-6, EBER1 & 2, BART,
LMP1 & 2, microRNAsMedit J Hemat Infect Dis 2009, 1(2), Open Journal System 
islands, are regularly found 5’ to coding sequences 
of  constitutively  expressed  „housekeeping” 
genes
30,31.  It  is  important  to  note,  however,  that 
most  CpG  island  promoters  are  unmethylated 
independently  of  their  activity
32,33.  Thus, 
mechanisms other than DNA methylation may also 
silence CpG island promoters.
In mammals 5-methylcytosine (confined to the 
sequence  5’-CpG-3’, shortly:  CpG)  is  the 
predominant  modified  base  found  in  DNA
34,35.  
Comparison of the  amino  acid  sequence of DNA 
methyltransferase  I  (DNMT1),  one  of  the 
mammalian  DNA  (cytosine-5)-methyltransferases, 
to  the  sequences  of  bacterial  methyltransferases 
suggested  that  DNMT1  arose  by  fusion  of  a 
prokaryotic  modification  methyltransferase  gene 
(coding for the C-terminal catalytic domain) and a 
second (unknown) gene, coding for a regulatory (N-
terminal) domain
36,37,38. A key feature of DNMT1 is 
its  preference  for  hemimethylated  DNA  as  a 
substrate.  Hemimethylated  DNA  molecules 
(consisting  of  one  methylated  strand  and  an 
unmethylated complementary strand) are regularly 
produced during DNA replication (provided that the 
parental strands were originally methylated). High 
affinity  of  DNMT1  for  hemimethylated  DNA 
ensures  the  clonal  propagation  of  methylation 
patterns  (maintenance  methylation).  Other 
mammalian  methyltransferases  (like  the human 
DNMT3A and DNMT3B) create new methylation 
patterns by acting on unmethylated DNA substrates 
(de novo methylation)
38. Their N-terminal domains 
differ from each other and from that of DNMT1
39. 
Methylated  CpG  dinucleotides  may  silence 
promoters either directly, by blocking the binding 
of  transcription  factors  to  their  recognition 
sequences, or indirectly, by attracting methyl-CpG 
binding  proteins.  Methyl-CpG  binding  proteins 
regularly  associate  with  histone  deacetylases  and 
histone methylases. Removal of the acetyl moieties 
from histone tails and methylation of selected lysine 
and  arginine  groups  results  in  a  repressive 
chromatin  structure  silencing  promoter 
activity
40,41,42.  These  alterations  may  switch  off 
active  promoters  and  stabilize the  silent  status  of 
already  inactivated  genes.  Riggs  proposed  that 
stable gene silencing by DNA methylation may help 
progeny cells to  „remember”  their proper cellular 
identity,  i.e.  DNA  methylation may  provide  a 
memory function
43.
Transcriptional repression may depend on CpG 
methylation density
33,44. CpG-poor promoters may 
retain their activity even if methylated. In somatic 
cells,  a  second  class  of    promoters  characterized 
with  a  moderate or intermediate  CpG density (so 
called  „weak  CpG  island  promoters”)  are 
preferentially  targeted  by  de  novo methylation
33. 
Typical CpG island promoters (called „strong CpG 
island  promoters” by  Weber  et  al.
33)  seem  to  be 
unmethylated independent  of  their  activity
33
although  they  are  regularly  inactivated  by  DNA 
methylation  in  neoplasms
44.  Thus,  focal 
hypermethylation  seems  to  accompany 
tumorigenesis in parallel or consecutive to overall 
genomic hypomethylation
45,46.
It is interesting to note, that an alternative system 
of  epigenetic  memory,  the  Polycomb-trithorax 
group of protein complexes, that may operate both 
independently  from  and  in  concert  with  DNA 
methylation, ensures a heritable regulation of gene 
expression  via  modification  of  histone  tails,  too 
(Bird, 2002, Cernilogar and Orlando, 2005, Laue et 
al., 2005). In animal cells certain sets of promoters 
are  marked  by  trimethylation  on  lysine  27  of 
histone H3 (H3K27me3), a modification carried out 
by the enzyme EZH2. EZH2, a component of the 
Polycomb repressive complex 2 (PRC2) involved in 
gene silencing in embryonal stem cells was recently 
shown to attract DNA methyltransferases
47 and may 
contribute, thereby, to permanent gene silencing via 
DNA hypermethylation in cancer cells
48,49. 
In  contrast  to  the  hypermethylated  silent 
promoters,  active  promoters  are  usually 
unmethylated  at  CpG  dinucleotides  and  associate 
with  acetylated  histones  H3  and  H4,  that  form 
’acetylation  islands’
50.  Histone  H3  di- or 
trimethylated on lysine 4 (H3K4me2, H3K4me3) is 
also enriched at active promoters. The presence of 
these „activating” chromatin modifications may not 
be sufficient, however, to ensure promoter activity 
because  certain  promoters  are  enriched  both  in 
„activating”  and  „repressive”  modifications 
(’bivalent’  chromatin structure)
51.  Such  ’bivalent’ 
domains  may  silence  developmental  genes  in 
embryonic  stem  cells.  In  addition,  Weber  et  al. 
observed  that  unmethylated  CpG  rich  promoters 
may also associate with H3K4me2 in the absence of 
transcription
33. 
Epigenetic mechanisms targeting the alternative 
latency promoters Cp and Qp in lymphoma cells 
and immortalized lympho-blastoid cell lines: The 
role of DNA methylation in regulating Cp and Qp 
activity  has  been  reviewed  earlier  (Li  and 
Minarovits, 2003). Briefly, both Cp and Qp can be 
silenced, when inserted into reporter constructs, by Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
in  vitro CpG  methylation.  Accordingly,  Cp  is 
hypermethylated  and  silent  in  tumor  cells 
corresponding  to  „Cp  off” latency  (including 
latency type I Burkitt’s lymphoma cells and latency 
type  II  Hodgkin’s  lymphomas),  but  unmethylated 
and  active  in  LCLs  and  the  majority  of 
posttransplant lymphomas („Cp on” latency)
24,52, 53, 
54.  Although  in  vitro data  demonstrated  thatCpG 
methylation could silence Qp as well
55,  Qp stays 
unmethylated independently of its activity (i.e. it is 
unmethylated  also  in  LCLs  where  it  is  switched 
off). Thus, DNA methylation may contribute to the 
silencing of Cp, but it is not used to silence Qp in 
vivo.
Episomal  EBV  genomes  are  organized  into 
chromatin
55. Similarly to cellular promoters
41, 56, the 
activity of latent EBV promoters Cp and Qp also 
correlated  with  certain  histone  modifications 
marking  „open” or  „closed”  chromatin 
domains
57,58,59,60. In lymphoblastoid cell lines active 
C promoters were located to AcH3 and AcH4 rich 
regions
60 that are similar to the ’acetylation islands’ 
characteristic to  the  active  chromatin  domains  in 
human  T  cells
50.  In  contrast,  in  type  I  Burkitt’s 
lymphoma cell lines there was no acetylation island 
at the inactive Cp. Active Qp, the promoter used in 
most  cases  of  „Cp  off” latency,  was  selectively 
enriched in AcH3, AcH4 and H3K4me2
59,60 in type 
I Burkitt’s lymphoma cell lines. In lymphoblastoid 
cell lines, however, the inactive Qp was located to 
domains poor in acetylated histones. 
It was demonstrated by in vivo footprinting that 
the  unmethylated,  active  Cp  was  occupied  by 
transcription  factors
53.  In  contrast,  the  absence  of 
interactions with activating transcription factors was 
characteristic  for  highly  methylated,  silent  C 
promoters. It is interesting to note, that epigenetic 
silencing of Cp may be regarded as a viral escape 
mechanism, because all of the transcripts encoding 
the  immunodominant  viral  EBNA  proteins  are 
initiated at Cp. Tumor cells actively using Cp can 
survive,  however,  in  severely  immunsuppressed 
patients (e.g. B cell lymphomas in transplantation 
recipients and AIDS patients).
We observed that the active, unmethylated  Qp 
was also contacted by cellular transcription factors 
and EBNA1, that in addition to oriP has binding 
sites  at  Qp  as  well
53.  In  contrast  to  Cp,  where 
silencing  was  correlated  with  the  loss  of 
transcription factor binding, silent Qp was marked 
by  the  same  protein  footprints  as  its  active 
counterpart. A unique footprint observed only at the 
silent  Q  promoters  suggested  that  binding  of  a 
cellular repressor might contribute to the repression 
of Qp activity in „Cp on” latency.
Epigenetic  marks  at  other  EBV  latency 
promoters:  In  vitro methylation  experiments 
demonstrated that Wp, where transcripts of EBNA1 
to 6 are initiated soon after EBV infection of B cells 
(Figure  3),  is  a  CpG  methylation sensitive 
promoter
61. Wp is switched off in LCLs, however, 
provided  that  Cp  is  intact,  in  parallel  with  the 
activation of Cp
62. A variable methylation of Wp in 
LCLs  suggests  that  epigenetic  mechanisms  other 
than  CpG  methylation  also  contribute  to  Wp 
silencing
63.
The  EBER  1  and  2  transcription  units  are 
transcribed by RNA polymerase III. Their activity 
is  also sensitive to  in vitro CpG methylation  that 
blocks binding of the  nuclear proteins c-myc and 
ATF  to  the  5’region  of  EBER1p
64.  EBERs  are 
expressed in the major EBV-carrying cell types and 
the EBER locus is hypomethylated
65.
LMP1  expression  can  be  related  to  the 
methylation status of the LMP1 promoter. In type I 
BL  lines  LMP1p is  silent and  highly  methylated, 
whereas  in  LCLs  and  midline  granulomas  it  is 
unmethylated  and  active  (reviewed  by  Li  and 
Minarovits,  2003).  In  contrast  to  Cp,  LMP1p 
activity did  not  correlate with  transcription factor 
occupancy
53. 
In  lymphoid  cell  lines,  expression  of  LMP2A 
seems to be regulated by the combinatorial effects 
of  DNA  methylation,  histone  acetylation  and  the 
level  of  histone  H3  dimethylated  on  lysine  4 
(H3K4me2, a marker of „open” chromatin)
66. 
The promoter for the BARTs (also called CSTs 
including  BARF0)  RNAs  was  found  to  be  active 
and  unmethylated  in  the  only  nasopharyngeal 
carcinoma cell line it was looked for
67.
Latent  Epstein-Barr  virus  proteins  interacting 
with  the  cellular  epigenetic  regulatory 
machinery:  We  demonstrated  above  that  various 
epigenetic  control  mechanisms  leave  cell  type 
specific marks on latent EBV genomes, establishing 
thereby  distinct  viral  epigenotypes  (reviewed  by 
Minarovits,
68).  In  turn,  certain  EBV  encoded 
proteins  may  interact  with  the  cellular  epigenetic 
regulatory machinery, affecting thereby the activity 
of a set of cellular promoters (Table 3). 
Because EBNA1 has binding sites in the human 
genome
69 and it is known that high affinity EBNA1 
binding can cause site specific demethylation within 
oriP, the  latent  origin  of  EBV  replication
70,  we 
suggest that binding of EBNA1 to its cellular target Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
Table 3. Latent Epstein-Barr virus products interacting with the cellular epigenetic regulatory machinery
Latency product  Cellular partner Putative outcome of the interaction
EBNA1 EBNA1 binding site site-specific demethylation of DNA; activation of adjacent genes;
EBNA2 histone acetyltransferases 
(p300, CBP, PCAF) transactivation of genes;
EBNA3C (EBNA6)
prothymosin alpha, p300; 
histone deacetylases 
(HDAC1 & 2)
modulating EBNA2-mediated transactivation 
EBNA-LP (EBNA5)
histone deacetylase 4 
(HDAC4) dispacement of HDAC4 from EBNA2-activated promoters; coactivation
LMP1
DNA methyltransferases 
DNMT1, 3a, 3b; hypermethylation mediated silencing of promoters;
Bmi-1 (a component of 
PRC1);
silencing of B cell specific and tumor suppressor genes;
marking a set of promoters for de novo methylation by DNMTases;
up-regulation of transcription (STAT-1, c-MET, HK);
via the NF-κB pathway: 
microRNA coding genes alteration of miR-146a and miR-1 level; modulation of cellular mRNA levels
sites may elicit local demethylation and contribute 
thereby  to  the  activation  of  silent  cellular 
promoters.  Lin  et  al.  demonstrated  in  model 
experiments that high affinity of the binding protein 
and  protein  binding  site  occupancy  is  crucial  in 
targeted demethylation
71.
EBNA2,  the  major  viral  transactivator  protein 
expressed in „Cp on” latency, may switch on both 
viral  (Cp,  LMP1p,  LMP2Ap)  and  cellular 
promoters (CD21p, CD23p, AML-2p, BATFp, IL-
16p)  (reviewed  by  Györy  and  Minarovits
72). 
EBNA2  activates  its  target  promoters  through 
binding to CBF1 (C promoter binding factor 1), a 
cellular protein that also interacts with the activated 
cellular  Notch  family  of  proteins
73-76.  In  vivo
footprinting confirmed CBF1 binding to the active 
C promoter and LMP2A promoter but not to their 
inactive  counterparts
53,77.  In  addition  to  CBF1, 
EBNA2  also  associates  with  the  cellular  histone 
acetyltransferases p300, CBP, and PCAF
78. Wang et 
al.
78 speculate that these histone acetyltransferases 
may enhance the ability of EBNA2 to up-regulate 
expression  of  the  viral  oncogene  LMP1  by 
counteracting  the  effect  of  histone  deacetylases 
associated with the silent LMP1 promoter
78.
EBNA3C (EBNA6), a nuclear antigen essential 
for EBV-dependent immortalization of  B cells may 
fine tune (down-modulate) the activity of EBNA2-
activated  promoters  by  interacting  and  competing 
with prothymosin alpha, a partner of  p300
79,80. In 
addition, EBNA3C may also form complexes with 
histone deacetylases (HDAC1 and 2) in human B 
cells
81. Knight et al
81 proposed that EBNA3C may 
be  in  separate  complexes  with  histone  acetylases 
and deacetylases affecting the function of distinct 
viral and cellular promoters.
In contrast to EBNA3C, the partly nuclear, parly 
cytoplasmic  antigen  EBNA-LP  (EBNA  leader 
protein,  EBNA5)  strongly  up-regulates  EBNA2-
mediated  transcription  by  relocalizing  the  histone 
deacetylase  HDAC4  from  the  nucleus  to  the 
cytoplasm
82.  Based on their observations Portal et 
al.
82 suggested  that  the  coactivator  function  of 
EBNA-LP is due to the reduction of the HDAC4 
concentration in the nucleus. They also speculated 
that  EBNA-LP  coactivates  with  EBNA2  by 
displacing  HDAC4  (and  HDAC4  associated 
repressors) from EBNA2-bound promoters. Recent 
data  do  not  support,  however,  the  nucleo-
cytoplasmic model for EBNA-LP mediated LMP1p 
coactivation,  because  an  EBNA-LP  isoform, 
defective  in  shuttling  to  the  cytoplasm,  could 
coactivate EBNA2 and associate with HDAC4
83.
LMP1,  a  transmembrane  protein  involved  in 
malignant transformation can affect both alternative 
systems  of  epigenetic  memory,  DNA  methylation 
and  the  Polycomb-trithorax  group  of  protein 
complexes.  Tsai  et  al.  observed,  however,  that 
expression of the EBV-encoded oncoprotein LMP1 
(latent membrane protein 1) in epithelial cells up-
regulated  the  expression  and  activity  of  cellular 
DNA  methyltransferases  1,  3a  and  3b  in  vitro
84. 
This resulted in hypermethylation of the E-cadherin 
promoter and down-regulation of E-cadherin gene 
expression. LMP1 activated DNMT1 via the c-jun 
NH(2)-terminal  kinase/activator  protein-1  (JNK-Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
AP-1) signaling  pathway
85.  In addition,  formation 
of a transcriptional repression complex (composed 
of  DNMT1  and  histone  deacetylase)  could  be 
detected  on  the  E-cadherin  promoter  as  a 
consequence of  LMP1 action. How this repressor 
complex was targeted to the E-cadherin promoter, 
however,  remains  to  be  elucidated.  These  results 
observed in epithelial cells are certainly very much 
relevant  to  the  development  of EBV-associated 
lymphomas as well, because latent EBV infection 
apparently results in hypermethylation of a set of 
cellular  promoters  not  only  in  nasopharyngeal 
carcinoma
86 and  EBV-associated  gastric 
carcinoma
87,88, but also in typically LMP1 positive 
Hodgkin lymphomas
89,90,91, iatrogenic lymphomas
92,
and lymphomas developing in AIDS patients
93.
Although the oncoprotein LMP1 can up-regulate 
the PcG protein Bmi-1
94, there are no data regarding 
the contribution of PcG (or trithorax group) proteins 
to  the  regulation  of  latent  EBV  promoters.  Up-
regulation of Bmi-1 is mediated by NF-κB signaling 
both in EBV-positive and EBV-negative Hodgkin’s 
lymphoma cells. Dutton et al.
94 suggested that by 
activating NF-κB, and thereby up-regulating Bmi-1, 
LMP1 may contribute to the loss of B-cell identity 
in EBV carrying Hodkins’s lymphomas via down-
regulating  a  series  of  B-cell  markers 
(CD21/MS4A1,  BLK,  LY9).  In  EBV-negative 
disease other activators of NF-κB may substitute for 
LMP1. We speculate that Bmi-1, as a component of 
polycomb repressor complex 1 (PRC1), may act by 
marking a set of promoters for de novo methylation 
by  DNA  methyltransferases.  In  addition,  Bmi-1, 
using  the  same  mechanism,  may  down-regulate  a 
series of tumor suppressor genes (including IGSF4 
and ATM), too. Bmi-1 also mediates up-regulation 
of certain genes that are  transcriptional targets of 
LMP1 (STAT1 and c-MET  and HK). These genes 
code  for  signaling  molecules  and  a  hexokinase 
maintaining  high  glycolytic  activity  and  seem  to 
play an important role in lymphomagenesis.
It is worthy to mention that LMP1 may affect the 
levels of certain cellular microRNAs (and modulate 
thereby  cellular  gene  expression  programs)  by 
activating  the  NF-κB  pathway.    LMP1  induced 
expression  of  miR-146a,  a  microRNA  that  may 
affect  the  interferon  response  (Cameron  et  al., 
2008),  and elevated  the  level  of  miR-155,  a 
microRNA implicated in the development of B cell 
lymphomas 
95.
Stem  cell  chromatin  patterns  in  B-cell 
lymphomas: Burkitt lymphomas (BLs) and diffuse 
large B-cell lymphomas (DLBCLs) seem to share a 
Table 4. Cellular genes silenced by promoter hypermethylation 
in  EBV-associated  lymphomas  and  derived  cell  lines.  For 
detailed discussion see Niller et al.
97
BL:  Burkitt’s  lymphoma;  HD:  Hodgkin’s  disease;  iatrogenic 
lymphomas  include  post-transplant  lymphoproliferative 
disorders (PTLDs) and methotrexate-related lymphomas.
Symbols:  frequent  inactivation  by  promoter  methylation,  +; 
infrequent  inactivation by promoter methylation, -/+; typically 
unmethylated promoter, -. 
set  of  de  novo methylated  genes  (e.g.  HOXB13, 
CALCA, NEFL, PROK2) that are repressed by the 
polycomb  repressive  complex  2  (PRC2)  in 
embryonic stem cells, in spite of the differences of 
BLs  and  DLBCLs  regarding  morphology,  genetic 
background,  and  transcriptional  pattern
96.  The 
aberrant DNA methylation observed in lymphomas 
was absent in adult stem and progenitor cells. Based 
on these data Martin-Subero et al.
96 suggested that 
BLs  and  DLBCLs  may  originate  from  cells  with 
Gene                                   
Lymphoma
BL  HD Iatrogenic/AIDS
-associated
ABF1  + -
BCL2-family (proapoptotic 
members)      +
BCMA +
BOB.1/OBF.1 +
CHK2 kinase +
Cyclin D2 +
CD19 +
CD20 +
CD79B +
CD59/HRF20 +
DAPK                                                 + ± +
DLC1 + ±
FHIT +
GADD25G +
GSTP1 +
LCK +
MAPK10/JNK3 + ±
O6-methylguanine-DNA 
MTase +
p16/CDK4A + ± -
p15/CDK4B       + ± -
p57/KIP2 +
p73 +
PCDH10 + +
PLK2 +
PU.1 +
PTPN13/FAP1 +
RASSF1A - + -
SYK +
WNT5A +Medit J Hemat Infect Dis 2009, 1(2), Open Journal System 
stem cell features or acquire such features during 
lymphomagenesis by epigenetic remodeling.
Tumor  specific  and  EBV-associated  gene 
expression  and  CpG  methylation  changes  in 
lymphomas: The epigenetic alterations of the host 
genomes  in  EBV-associated  neoplasms 
(lymphomas  and  carcinomas)  were  reviewed 
recently
97. 
It  is  obvious  that  certain  common  tumor 
suppressor and tumor-associated genes were found 
to be silenced by DNA methylation in more than 
one  lymphoma  types  in  independent studies.  One 
could  also  discern,  however,  methylation  profiles 
that  seem  to  be  unique  for  individual  lymphoma 
types. The apparently specific contribution of EBV 
to the alteration of gene expression in HD biopsies
98
remains  to  be  correlated  with  the  corresponding 
epigenetic  changes.  Elucidation  of    the  temporal 
sequence  of    genetic  events  (e.g.  the  Ig/c-myc 
translocation  in  BL),  epigenetic  alterations  (e.g. 
stem  cell-like  epigenetic  marks  of  BL  cells)  and 
EBV infection (an early event during the genesis of 
BL)  will  be  indispensable  in  case  of  each  EBV 
positive lymphoma type for a better understanding 
of    lymphoma  development  and  progression.  In 
addition, the patho-epigenetic changes induced by 
EBV,  similarly  to  those  elicited  by  a  growing 
number of other viruses and certain bacteria  may 
offer new opportunitis for therapeutic intervention.
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